Leadership Overview
Darya-Varia has 4 executives leading key functions including finance, operations, and governance.
Driven by a mission to build a healthier Indonesia, Darya-Varia is committed to providing high-quality health facilities and products through strategic initiatives and a steadfast focus on quality and safety.
Driven by a mission to build a healthier Indonesia, Darya-Varia is committed to providing high-quality health facilities and products through strategic initiatives and a steadfast focus on quality and safety.
Leadership Roles at Darya-Varia
Celso Lim - Chief Financial Officer
Celso Lim, the Chief Financial Officer at Darya-Varia, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and financial reporting, the Chief Financial Officer ensures robust financial health across the organization. This leadership role involves managing capital allocation, optimizing investment strategies, and maintaining strong relationships with financial institutions. By analyzing market trends and economic indicators, Celso Lim drives financial performance and supports sustainable growth initiatives. The Chief Financial Officer's expertise is critical in navigating the complex financial landscape of the pharmaceutical manufacturing sector, ensuring compliance with regulatory requirements and maximizing shareholder value. Lim's strategic financial management underpins the company's ability to invest in research, development, and expansion, directly impacting Darya-Varia's long-term viability and market position.
Clinton Hess - President & Commissioner
Clinton Hess, the President & Commissioner at Darya-Varia, leads the strategic direction and governance of the company. This dual role encompasses executive leadership and board oversight, ensuring alignment between operational execution and long-term corporate objectives. The President & Commissioner directs key initiatives aimed at enhancing Darya-Varia's market presence and product portfolio, particularly in soft gelatin capsules, liquid preparations, and medicinal plasters produced at the Gunung Putri Plant. Hess's leadership ensures the effective implementation of the Integrated Management System across all facilities, maintaining ISO certifications and halal guarantees. By fostering collaboration between operational teams and the Board, Clinton Hess drives innovation and operational efficiency, supporting the mission of building a healthier Indonesia. This executive guides the company's growth trajectory and commitment to quality healthcare solutions.
Ian Kloer - President & Director
Ian Kloer, the President & Director at Darya-Varia, spearheads the company's operational execution and strategic growth initiatives. This leadership position involves overseeing the production of sterile injection products and solid preparations at the Citeureup Plant, alongside managing the Toll Manufacturing business through PT Medifarma Laboratories. Kloer directs technology transfer, lab trials, and commercial production for both domestic and international markets, ensuring high-quality finished goods. The President & Director champions the company's commitment to quality and safety, evidenced by numerous ISO and SNI certifications, and the adherence to halal guarantee systems across all facilities. Ian Kloer's strategic oversight ensures Darya-Varia consistently meets market demands and upholds its mission of providing accessible, high-quality health facilities, driving progress for 45 years.
Sancoyo Antarikso - Independent Commissioner
Sancoyo Antarikso, the Independent Commissioner at Darya-Varia, provides objective oversight and strategic guidance to the Board of Commissioners. This role involves critically evaluating management's proposals, ensuring adherence to corporate governance best practices, and safeguarding the interests of all stakeholders. The Independent Commissioner's responsibilities include reviewing financial statements, assessing business strategies, and advising on risk management frameworks. Antarikso's independent perspective is vital for maintaining transparency and accountability within the organization. By championing ethical conduct and sound business principles, Sancoyo Antarikso contributes to the long-term stability and integrity of Darya-Varia's operations. This position is crucial for fostering trust and confidence among investors, employees, and the wider community, reinforcing the company's commitment to excellence in healthcare provision.
Explore Leadership Teams in Manufacturing
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel.
Company Leadership
MP
MT
Chemipharm is the only company selling directly to 100% of the reachable pharmacies and hospitals in Egypt. Chemipharm's distribution network includes: 12 branches allover Egypt. 100 fixed routes every day. Total 150 visiting all the pharmacies all over the country. Latest News : PROFILE Company Profile: Chemipharm was founded in 1972 by Dr. Gamal Kamel as the first private sector importer of pharmaceutical products in Egypt. Over the last 35 years, Chemipharm has developed and maintained an invaluable reputation as Egypt's most respectable and high standards pharmaceutical distributor. In 2003, based on the company's continuous growth, Chemipharm has established its own manufacturing facility in the 6th of October Industrial Zone. Plant was designed by Pharma Consult. The modern GMP plant produces pharmaceutical products of all major forms (tablets, capsules, syrups and ointments). Presently Chemipharm is constructing a new sterile area to produce ampoules, eye drops and antibiotics. The company's strategy is based on continuous improvement and growth.
Company Leadership KK
DO
NM
Gland Pharma Limited is a rapidly growing global manufacturer of generic injectables, supplying to markets including the United States, Europe, Canada, Australia, and India. The company specializes in complex injectables, oncology, and ophthalmics, leveraging its robust R&D and manufacturing capabilities. Established in 1978 in Hyderabad, India, Gland Pharma has expanded its operations to over 60 countries, focusing on a business-to-business model. With a commitment to high-quality and affordable products, Gland Pharma aims to meet diverse injectable needs across the pharmaceutical industry.
Company Leadership RP
AW
RM
KR
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Darya-Varia Top Executives and Leadership Team
